N4 Pharma PLC (LSE:N4P) — Market Cap & Net Worth
Market Cap & Net Worth: N4 Pharma PLC (N4P)
N4 Pharma PLC (LSE:N4P) has a market capitalization of $48.10K (GBX395.33 Million) as of September 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31645 globally and #1214 in its home market, demonstrating a -9.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying N4 Pharma PLC's stock price GBX0.48 by its total outstanding shares 832280349 (832.28 Million). Also see balance sheet size of N4 Pharma PLC for a full breakdown of the balance sheet.
N4 Pharma PLC Market Cap History: 2015 to 2026
N4 Pharma PLC's market capitalization history from 2015 to 2026. Data shows change from $222.78K to $48.10K (-16.24% CAGR). Also see N4 Pharma PLC (N4P) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
N4 Pharma PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$902.54 Million | 0.01% | #422 of 722 |
Weight: N4 Pharma PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
N4 Pharma PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how N4 Pharma PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check N4P stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
7.30x
N4 Pharma PLC's market cap is 7.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $506.32K | $1.16 Million | -$22.00K | 0.44x | N/A |
| 2017 | $1.03 Million | $109.91K | -$1.84 Million | 9.33x | N/A |
| 2018 | $946.82K | $72.83K | -$1.19 Million | 13.00x | N/A |
| 2023 | $86.07K | $1.95K | -$1.27 Million | 44.07x | N/A |
| 2024 | $53.16K | $7.28K | -$1.06 Million | 7.30x | N/A |
Competitor Companies of N4P by Market Capitalization
Companies near N4 Pharma PLC in the global market cap rankings as of September 18, 2026. Review how tangible is N4 Pharma PLC's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to N4 Pharma PLC by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #519 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #633 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #640 globally with a market cap of $43.16 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.62 Billion USD ( CN¥277.61 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #519 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #633 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #640 | GALDERMA GROUP AG | NYSE:GALDY | $43.16 Billion | $37.02 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.62 Billion | CN¥43.52 |
N4 Pharma PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, N4 Pharma PLC's market cap moved from $222.78K to $ 48.10K, with a yearly change of -16.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX48.10K | -9.52% |
| 2025 | GBX53.16K | 0.00% |
| 2024 | GBX53.16K | -38.24% |
| 2023 | GBX86.07K | -54.05% |
| 2022 | GBX187.34K | -59.78% |
| 2021 | GBX465.82K | -44.91% |
| 2020 | GBX845.56K | +203.64% |
| 2019 | GBX278.48K | -70.59% |
| 2018 | GBX946.82K | -7.65% |
| 2017 | GBX1.03 Million | +102.50% |
| 2016 | GBX506.32K | +127.27% |
| 2015 | GBX222.78K | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of N4 Pharma PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.10K USD |
| MoneyControl | $48.10K USD |
| MarketWatch | $48.10K USD |
| marketcap.company | $48.10K USD |
| Reuters | $48.10K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About N4 Pharma PLC
N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequen… Read more